

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

KEN-VALVE REGISTRATION APPLICATION ENTERS NMPA PRIORITY APPROVAL PROCESS

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, the registration application of Ken-Valve, the transcatheter prosthetic aortic heart valve system independently developed by the Company, has successfully entered the priority approval process (the “**Priority Approval Process**”) of the National Medical Products Administration (“**NMPA**”) for medical devices.

For projects entering into the Priority Approval Process, the NMPA will speed up the appraisal and approval procedures in all aspects to shorten the time for rolling-out of products and ensure that the corresponding achievements and products can be soon applied to clinical use. Up to now, only eight products have been approved by the NMPA for priority approval in 2023. Meanwhile, Ken-Valve is the first product in the field of heart valves selected to enter the Priority Approval Process since NMPA opened the priority approval channel.

The Ken-Valve transcatheter prosthetic aortic valve system was independently developed by the Company, and the indications can cover patients with both aortic valve closure insufficiency or combined aortic valve stenosis. Ken-Valve offers treatment options and solutions for the unmet need for aortic regurgitation in a market with a large reservoir of patients in need of rescue as well as incremental patients with increasing prevalence. Its multiple advanced design highlights have the advantage of significantly reducing the risk of serious adverse events and increasing procedural success.

Ken-Valve has been submitted and accepted for registration which is the second core product of the Company submitted for registration following Lux-Valve, the transcatheter tricuspid valve replacement system independently developed by the Company. Its inclusion in the Priority Approval Process will significantly increase the speed of obtaining registration and approval and accelerate the commercialization of the product.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize Ken-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, October 30, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.